unit report sales/earn provid
busi updat compani end record quarterli
annual revenu also saw greater anticip opex increas
highlight dynam variou investor confer slightli adjust
estim reflect account benefit stronger
revenu tax reform larg off-set drag increas opex
expect dynam year adcirca patent loss may potenti
remodulin gener entri freedom-ev pivot phase
data strengthen treprostinil franchis earn
leverag opex control/tax reform stay bullish
beat revenu expect see miss
earn expect investor focus increas opex
greater anticip howev note earn expect
model essenti stay steadi strengthen revenu tax reform benefit
highlight off-set increas opex
near-term focu regulatori statu remosynch remun
pump remosynch system aim iv remodulin user
sbla resubmit late januari await fda notif
whether class class file end februari remun subq
remodulin file complet februari
conserv assum six-month approv time-frame remosynch
class sbla month remun lead launch
product could lead minim loss gener remodulin
entri anticip late june agreement sandoz limit
gener current remodulin formul effect remosynch
frame refer bbg consensu assum loss remodulin
sale vs opco success launch two pump
mitig near-term loss see benefit
earn steadfast belief expect
consensu remodulin sale loss high
seven phase pipelin project develop led
 expens grow faster rate expect expect
continu strong revenu opex leverag tax reform benefit
mitig impact earn phase project freedom-ev
tyvaso continu expect readout
biotech compani focus
develop commerci
innov product address unmet
medic need patient chronic
life-threaten condit
analyst certif import disclosur see disclosur appendix
trade compress multipl peer group
believ street under-appreci strength
busi model strong experienc
manag team newli launch product pipelin
help bridg patent cliff get back growth
bullish
slow loss remodulin tyvaso flolan
dynam model losses/year
adcirca patent loss complet
orenitram freedom-ev studi posit final readout
tyvaso studi posit
orenitram hit sale
quarterli sale updat orenitram remodulin tyvaso
effect competitor uptravi
statu fda applic launch strategi remodulin
readout freedom-ev
competit updat actelion own
remodulin pump tyvaso/beraprost combin
product growth
tyvaso posit phase lead growth product post-
loe
orenitram reach sale
success addit indic treprostinil organ
transplant busi and/or oncolog mid-term two three
freedom-ev neg final readout
orenitram sale ramp slows/flatten orenitram
remodulin tyvaso gener loss greater anticip
loss orenitram ip prior patent expir beyond
arriv pt util composit valuat methodolog biotechnolog compani base forward price-to-earnings multipl
net present valu non-gaap estim earn peer index nbi expect earn compound-annual-growth-rate growth
next three five year base case ascrib multipl equal peer
group averag due risk uthr loss exclus loe three lead product start late wacc
reflect increas visibl product sale
downsid risk faster eros remodulin tyvaso adcirca sale expect gener entrant prior
time-frame heighten competit orenitram achiev blockbust statu greater sale next decad
unit statement million product other- total product adj research adj sell gener estim loss contingency- adj total oper oper interest interest income- total expens incom report incom continu adj effect incom tax report incom continu incom discontinu operations- adj net dilut dilut share unit
unit statement million product total product adj research adj sell gener estim loss contingency- adj total oper oper interest expense- interest income- total expens incom report incom continu adj effect incom tax report incom continu incom discontinu operations- adj net dilut dilut share comp sale outperform
stock price compani mention report
bloomberg price
